MedTrace Logo

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

NCT03511625 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-01-30

No results posted yet for this study

Summary

Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.

Conditions

Interventions

DRUG

Acthar Injectable Product

Acthar is a non-specific melanocortin receptor agonist

DRUG

Depo medrol

Depo medrol is an anti-inflammatory glucocorticoid

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Attune Health Research, Inc.

    lead INDUSTRY

Principal Investigators

  • Swamy R Venuturupalli, MD, FACR · CEO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-02
Primary Completion
2020-02-26
Completion
2024-12-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03511625 on ClinicalTrials.gov